Clinical Trial Update: Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lurbinectedin with durvalumab in pre-treated patients with extensive-stage small-cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Platinum-sensitive Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Zepzelca (lurbinectedin)

Snippet

Sponsor: Institut Bergonié | Conditions: Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma | Phase 2 | Status: WITHDRAWN